Generative AI-Designed TEAD Inhibitor Shows 40% Response Rate in Heavily Pretreated Mesothelioma
A Phase 1 trial presented at ESMO 2026 reports a 40% objective response rate at 130 mg for ISM6331, a ...
A Phase 1 trial presented at ESMO 2026 reports a 40% objective response rate at 130 mg for ISM6331, a ...
A Stanford-developed virtual biotech used 37,000 AI agents to analyze 50,000 trials, identify markers linked to drug success and design ...
Insilico Medicine's executive team will deliver keynotes and panels at five AI and biopharma conferences in Dubai, Hong Kong, Seoul, ...
A new review argues that AI-driven antiviral discovery must be benchmarked against respiratory RNA virus polymerases under virologically realistic conditions ...
A team at Nanjing Medical University used RFdiffusion to design a CLDN18.2-targeting T-cell engager for gastric cancer and showed that ...
The latest volume of SLAS Discovery showcases how artificial intelligence, deep learning and data-mining strategies are accelerating drug discovery across ...
Researchers used machine learning, docking, and molecular dynamics to transform Traditional Chinese Medicine compounds into optimized computational leads against E. ...
Researchers have built ProteinTalks, an AI virtual cell model trained on more than 38 million time-resolved protein measurements from perturbed ...
Researchers combined LightGBM, Random Forest, and XGBoost models with docking and molecular dynamics simulations to identify three novel serotonin transporter ...
A new review maps how artificial intelligence is transforming oncology drug discovery, clinical decision-making, and regulatory science from molecule design ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine